BioAtla, Inc.
Business
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics that selectively target solid tumor microenvironments. It develops and advances CAB antibodies and derived modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), T cell-engaging bispecifics and CAR-T constructs, leveraging a Protein-activated Chemical Switch (PaCS) discovery approach. Its operations center on a clinical and preclinical pipeline of CAB product candidates, intellectual property management and strategic collaborations. BioAtla pursues global regulatory approvals and commercialization via third-party manufacturing and partnerships across the United States, European Union, China and other international markets.
Summary from filing dated 2025-03-28
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-59.61M |
| Total assets | — |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | $-48.20M |